ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

NCT05245760 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Funding unavailable.

Conditions

Esophageal Cancer
Esophagogastric Junction Cancer

Interventions

DRUG: Intravenous Tislelizumab
DRUG: Chemotherapy
RADIATION: Fractionated radiation
PROCEDURE: Esophagectomy

Sponsor

Zhonglin Hao

Collaborators

[object Object]
[object Object]